NCT07439653ClinicalTrials.gov
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
En resumen
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Fase 1 / Fase 2155 participantes buscados9 centros1 país
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07439653Abrir este registro en ClinicalTrials.govSincronizado hace 2 meses
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 3 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 155 participants (target), run at 9 sites.
How this score is built
- Enrolment21/40
155 participants (target)
- Site count6/25
3 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 43 months
- Sponsor scale3/10
TORL Biotherapeutics, LLC has led 10 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Afecciones
- Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 1 / Fase 2 |
| Asignación | No aleatorizado |
| Modelo de intervención | SEQUENTIAL |
| Propósito principal | TREATMENT |
| Enmascaramiento | NONE (0) |
| Inscripción | 155 participantes buscados |
Patrocinador y colaboradores
- TORL Biotherapeutics, LLC Patrocinador
Grupos e intervenciones
- Part 1: Monotherapy Dose EscalationEXPERIMENTAL
TORL-5-700 Administered once every three weeks
- Part 2: Monotherapy ExpansionEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks
- Part 3: Combination EvaluationEXPERIMENTAL
TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent
Intervenciones
- Fármaco TORL-5-700
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
- Fármaco TORL-5-700 at MTD/RP2D
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
- Fármaco TORL-5-700 at MTD/RP2D in combination with another agent
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent
Variables de resultado
Variable de resultado principal
Evaluate the safety of TORL-5-700 as a monotherapy
Assessment of adverse events according to NCI-CTCAE Version 5.0
Plazo though study completion, an average of 2.5 years
Variable de resultado principal
Assess the antitumor activity of TORL-5-700 as monotherapy
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria
Plazo though study completion, an average of 2.5 years
Variable de resultado principal
Evaluate the safety of TORL-5-700 in combination with other agents
Assessment of adverse events according to NCI-CTCAE Version 5.0
Plazo though study completion, an average of 2.5 years
Variable de resultado principal
Determine the Maximum Tolerated Dose (MTD)
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)
Plazo 21 days from the start of treatment
Variable de resultado principal
Determine the Recommended Phase 2 Dose (RP2D)
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities
Plazo 21 days from the start of treatment
Variable de resultado secundaria
Maximum Serum Concentration of TORL-5-700 (Cmax)
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Terminal Half-life (t1/2) of Serum TORL-5-700
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Clearance (CL) of TORL-5-700
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Clearance (CL) of TORL-5-700 in combination with other agents
Pk assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Volume of distribution of TORL-5-700
PK assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Volume of distribution of TORL-5-700 in combination with other agents
PK assessment
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Immunogenicity of TORL-5-700
Immunogenicity will be measured by incidence of treatment emergent ADAs
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Immunogenicity of TORL-5-700 in combination with other agents
Immunogenicity will be measured by incidence of treatment emergent ADAs
Plazo though end of study treatment, an average of 5 months
Variable de resultado secundaria
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria
Plazo though study completion, an average of 2.5 years
Fechas
| Fecha de inicio | 31 de marzo de 2026 (real) |
|---|---|
| Finalización principal | 31 de marzo de 2029 (estimada) |
| Finalización | 30 de septiembre de 2029 (estimada) |
| Primera publicación | 27 de febrero de 2026 (real) |
| Última actualización | 28 de septiembre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | agosto de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
9 centros están en reclutamiento
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| University of Texas Southwestern Medical Center | Dallas | Texas | En reclutamiento |
| Providence Medical Foundation | Fullerton | California | En reclutamiento |
| University of Iowa Health Care | Iowa City | Iowa | En reclutamiento |
| Cancer and Blood Specialty Clinic, Los Alamitos | Los Alamitos | California | En reclutamiento |
| University of California Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | En reclutamiento |
| Sarah Cannon Research Institute | Nashville | Tennessee | En reclutamiento |
| UCLA | Santa Monica | California | En reclutamiento |
| Stanford University | Stanford | California | En reclutamiento |
| Cancer Center of Kansas, Wichita | Wichita | Kansas | En reclutamiento |
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 28 de septiembre de 2026
Centro añadido
3 sites added (9 total)
69
- 24 de agosto de 2026
Centro añadido
3 sites added (6 total)
36